Biogen Inc. reported a Q1 2026 earnings beat but issued lower full-year guidance due to increased R&D spending and pressure on older multiple sclerosi...
Bullish
Artemis Investment Management LLP has acquired 226,845 shares of Biogen Inc. (NASDAQ:BIIB) during the fourth quarter, valued at approximately $39.9 mi...
Biogen (BIIB) has seen a 51.7% return over the last year, with its share price closing at US$180.67. A Discounted Cash Flow (DCF) analysis suggests th...
Bullish
UBS has upgraded Biogen Inc. (BIIB) to Buy from Neutral, increasing its price target to $225, citing upcoming pipeline catalysts within the next 12-15...
Bullish
The Avonex market is projected for significant growth, reaching $2.58 million by 2030, driven by increasing multiple sclerosis diagnoses and advanceme...
Bullish
Biogen recently acquired full global control of felzartamab, a Phase 3 anti-CD38 antibody, by securing the exclusive Greater China rights for up to US...
Neutral
UBS has upgraded Biogen (NASDAQ:BIIB) from Neutral to Buy and increased its price target to $225 from $185, citing increasing conviction on multiple p...
Neutral
Biogen Inc (BIIB) shares surged 3.4% to $183.34, leading to a "fairly valued" verdict from GF Value™ despite being 8.6% undervalued compared to the $2...
Bullish
Biogen Inc. is at a critical juncture, with stabilizing multiple sclerosis sales and emerging Alzheimer's treatments like Leqembi. The company's futur...